Volume 23, Number 4Bladder CancerUnmet Needs in High-Risk Non–Muscle-Invasive Bladder Cancer From the Patient’s Perspective: Challenges and Potential SolutionsAshish KamatJason HafronNon–muscle-invasive bladder cancer (NMIBC) represents about 75% of bladder cancer cases, often leading to recurrence, considerable emotional distress, and a decline in health-related quality of life for affected patients. There are substantial unmet treatment needs for patients with NMIBC.Quality of lifenon-muscle invasive bladder neoplasmstransurethral resection of bladderBCG vaccinepatient satisfaction
Volume 23, Number 3Bladder CancerImmune Checkpoint Inhibitors for the Treatment of Non–Muscle-Invasive Bladder Cancer: An Overview of Ongoing Clinical TrialsNeal D ShoreTreatment of non–muscle-invasive bladder cancer (NMIBC) is evolving, seeking new treatments to overcome the limitations of bacille Calmette-Guérin therapy and alternatives to radical cystectomy. Studies are currently evaluating the safety and efficacy of immune checkpoint inhibitors in combination with bacille Calmette-Guérin vs bacille Calmette-Guérin monotherapy for patients with high-risk NMIBC that is bacille Calmette-Guérin naive or recurrent after bacille Calmette-Guérin induction. We briefly summarize 4 studies that are evaluating intravenous immune checkpoint inhibitors (atezolizumab, durvalumab, and pembrolizumab) and 1 subcutaneous immune checkpoint inhibitor (sasanlimab). These studies may substantially change standard-of-care treatment for patients with high-risk NMIBC.immune checkpoint inhibitorsMonoclonal antibodiesClinical trialsnon-muscle invasive bladder neoplasms